Across TCGA pan-cancer cohorts, LINC02184 RNA differs between tumor and matched normal tissue in 1 of 18 cancer types tested, making tumor–normal expression one of LINC02184’s most consistent transcriptional readouts.
The strongest signal is observed in lung adenocarcinoma (LUAD), where LINC02184 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types LINC02184 is over-expressed in tumor.
LUAD are the cancer types where LINC02184 tumor–normal differential expression is most reproducible.